03 Aug , 2026 By : Debdeep Gupta
Zydus Lifesciences share price will remain in focus on August 3 following the company received Establishment Inspection Report (EIR) for its Ahmedabad facility.
The company said it has received an EIR from the US Food and Drug Administration (USFDA) for its injectable manufacturing facility at Zydus Biotech Park, Ahmedabad, with a Voluntary Action Indicated (VAI) classification.
The facility underwent a Good Manufacturing Practices (GMP) surveillance inspection between April 27 and May 5, 2026.
Separately, the drugmaker said its board will meet on August 11 to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
The company recently received permission to begin a Phase III clinical trial of Desidustat for treating anemia in patients with sickle cell disease. The 203-day study, being conducted in collaboration with the Indian Council of Medical Research (ICMR), will evaluate the efficacy and safety of the oral therapy.
In the previous trading session, the share closed at Rs 1,126.50, up Rs 11.00, or 0.99 percent.
The share touched a 52-week high of Rs 1,181 and a 52-week low of Rs 835.85 on 08 July, 2026 and 02 April, 2026, respectively. Currently, the stock is trading 4.61 percent below its 52-week high and 34.77 percent above its 52-week low.
The market capitalisation of the company stands at Rs 113,352.26 crore.
0 Comment